Related references
Note: Only part of the references are listed.Systematic Functional Annotation of Somatic Mutations in Cancer
Patrick Kwok-Shing Ng et al.
CANCER CELL (2018)
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Margaret K. Callahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Tuba N. Gide et al.
CLINICAL CANCER RESEARCH (2018)
Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib
Steven A. Lacy et al.
CLINICAL PHARMACOKINETICS (2017)
Whole-genome landscapes of major melanoma subtypes
Nicholas K. Hayward et al.
NATURE (2017)
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations
Ioana Cosgarea et al.
ONCOTARGET (2017)
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines
Bradley Garman et al.
CELL REPORTS (2017)
A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma
Clemens Krepler et al.
CELL REPORTS (2017)
Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel
de Unamuno Bustos Blanca et al.
SCIENTIFIC REPORTS (2017)
Cutaneous adverse effects of the immune checkpoint inhibitors
Lindsey K. Collins et al.
CURRENT PROBLEMS IN CANCER (2017)
Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars
Christian Jackisch et al.
BREAST (2017)
GEIS guidelines for gastrointestinal sarcomas (GIST)
Andres Poveda et al.
CANCER TREATMENT REVIEWS (2017)
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Clemens Krepler et al.
CLINICAL CANCER RESEARCH (2016)
Identification of a Novel Pathogenic Germline KDR Variant in Melanoma
Ines P. Silva et al.
CLINICAL CANCER RESEARCH (2016)
Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Maria Romina Girotti et al.
CANCER DISCOVERY (2016)
Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making
Ricardo De Paoli-Iseppi et al.
PATHOLOGY (2016)
Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience
Jose Manuel Ruiz-Morales et al.
THERAPEUTIC ADVANCES IN UROLOGY (2016)
Peroxiredoxin 6 triggers melanoma cell growth by increasing arachidonic acid-dependent lipid signalling
Alexandra Schmitt et al.
BIOCHEMICAL JOURNAL (2015)
ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas
Claudia Capparelli et al.
CANCER RESEARCH (2015)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors
Rashmi S. Goswami et al.
CLINICAL CANCER RESEARCH (2015)
Beyond BRAFV600: Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma
Alan E. Siroy et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients
Katharina Koenig et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genetics of familial melanoma: 20 years after CDKN2A
Lauren G. Aoude et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
Tissue-based map of the human proteome
Mathias Uhlen et al.
SCIENCE (2015)
RET Y791F: alone or accompanied?
Rodrigo A. Toledo et al.
ARCHIVES OF ENDOCRINOLOGY METABOLISM (2015)
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Helen Rizos et al.
CLINICAL CANCER RESEARCH (2014)
Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects
Klaus G. Griewank et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Georgina V. Long et al.
NATURE COMMUNICATIONS (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Karen E. Sheppard et al.
CLINICAL CANCER RESEARCH (2013)
EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
Alberto Antonicelli et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2013)
Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loops
J. A. G. C. Laisney et al.
ONCOGENE (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma
Ken Dutton-Regester et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
Sergey I. Nikolaev et al.
NATURE GENETICS (2012)
HER2 Evaluation and Its Impact on Breast Cancer Treatment Decisions
K. A. B. Goddard et al.
PUBLIC HEALTH GENOMICS (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Predicting Functional Significance of Cancer-Associated p16INK4a Mutations in CDKN2A
Heather A. McKenzie et al.
HUMAN MUTATION (2010)
High Frequency of p16 INK4A Promoter Methylation in NRAS-Mutated Cutaneous Melanoma
Anders Jonsson et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations
Maria Lisa Dentici et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2009)
Functional, Structural, and Genetic Evaluation of 20 CDKN2A Germ Line Mutations Identified in Melanoma-Prone Families or Patients
Caroline Kannengiesser et al.
HUMAN MUTATION (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Predicting the risk of pancreatic cancer:: On CDKN2A mutations in the melanoma-pancreatic cancer syndrome in Italy
Paola Ghiorzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Rewired ERK-JNK signaling pathways in melanoma
Pablo Lopez-Bergami et al.
CANCER CELL (2007)
RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor
IP Menacho et al.
CANCER RESEARCH (2005)
The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk
B Frank et al.
CARCINOGENESIS (2005)
An unusual FGFR1 mutation (fibroblast growth factor receptor 1 mutation) in a girl with non-syndromic trigonocephaly
W Kress et al.
CYTOGENETICS AND CELL GENETICS (2000)
Share Paper
